{"id":900,"date":"2026-03-06T10:31:01","date_gmt":"2026-03-06T10:31:01","guid":{"rendered":"https:\/\/de.vivosight.com\/?page_id=900"},"modified":"2026-04-22T18:46:26","modified_gmt":"2026-04-22T17:46:26","slug":"clinical-applications","status":"publish","type":"page","link":"http:\/\/de.vivosight.com\/en\/clinical-applications\/","title":{"rendered":"Clinical Applications"},"content":{"rendered":"
\n
\n\n
\n
\n

Non-Melanoma Skin Cancer (NMSC)
\nDiagnosis & Follow-Up<\/p>\n <\/div>\n <\/div>\n\n <\/div>\n

\n \"\"\n <\/div>\n<\/section>\n\n
\n
\n\n
\n
\n

Faster, non-invasive insight
\r\nfor confident BCC diagnosis<\/h2>\n
\n

OCT skin imaging to simplify diagnosis, follow-up and clinical workflow.<\/p>\n <\/div>\n

\n

VivoSight Dx Pro delivers rapid, non-invasive OCT imaging that supports accurate BCC diagnosis and treatment follow-up \u2014 without routine biopsy.<\/p>\n

OCT imaging is now Included in the European Consensus Guidelines for Diagnosis & Treatment of BCC, SCC & AK; and in many national Guidelines, including those of Germany and The Netherlands.<\/p>\n <\/div>\n

\n Schedule your online demo<\/a>\n <\/div>\n <\/div>\n
\n \"VivoSight <\/div>\n <\/div>\n\n <\/div>\n<\/section>\n\n
\n
\n\n
\n
\n
\n
\n

Professor Paasch, a practising dermatologist in Germany, explains how VivoSight OCT and VivoAID support confident, non-invasive diagnosis and streamline clinical workflow in routine practice.<\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n
\n